local advanced breast cancer
Recently Published Documents


TOTAL DOCUMENTS

25
(FIVE YEARS 3)

H-INDEX

6
(FIVE YEARS 0)

2021 ◽  
Author(s):  
Yojiro Ishikawa ◽  
Rei Umezawa ◽  
Takaya Yamamoto ◽  
Noriyoshi Takahashi ◽  
Kazuya Takeda ◽  
...  

Abstract Background: Patients with breast cancer who refuse standard treatment often suffer from malignant wounds due to the growth of local tumors. However, treatment strategies for patients with unresectable locally advanced breast cancer who have refused standard treatment have been unclear.Case presentation: A 44-year-old female was diagnosed with breast cancer of mucinous carcinoma in the right breast. She refused standard treatment for her breast cancer for six years. She suddenly visited the emergency department because of acute bleeding from the right breast cancer with malignant wounds. Macroscopically, the tumor in the right breast measured over 20 cm in diameter. The tumor was exudative, exhibited ulceration and slight bleeding, and gave off an odor. Imaging findings showed multiple lymph node and bone metastases, and the final diagnosis was breast cancer of stage IV (cT4bN1M1). Although the surgeon recommended chemotherapy for the breast cancer, the patient refused to receive chemotherapy or other therapy due to concerns about complications during treatment. Considering the symptoms of advanced breast cancer with malignant wounds, she finally agreed to receive radiation therapy (RT). We performed RT of 70 Gy in 35 fractions over a period of 7 weeks. The tumor-associated symptoms were disappeared after RT. At three months after RT, the tumor had almost disappeared. We administered luteinizing hormone-releasing hormone agonists after RT. At two years after RT, she died due to multiple liver metastases and appearance of ascites; however, there was no disease progression in the right breast.Conclusions: High-dose RT for local advanced breast cancer of MC with malignant wounds is therefore considered to be an effective therapeutic option.


2020 ◽  
Vol 46 (2) ◽  
pp. e65
Author(s):  
Eva Ruvalcaba-Limon ◽  
Veronica Bautista-Piña ◽  
Flavia Morales-Vasquez ◽  
Julio Ramirez-Bollas ◽  
Pabel Miranda-Aguirre

2018 ◽  
Vol 1 (2) ◽  
pp. 1-11
Author(s):  
Muhammad Danar Deswangga ◽  
Yamin Alsoph

ABSTRACT Introduction. Cancer until now has become a problem for health in the world including Indonesia. According to 2013 WHO data, cancer incidence has increased from 12.7 million cases in 2008 to 14.1 million cases in 2012. In local advanced breast cancer the treatment is neoadjuvant chemotherapy. Neoadjuvant therapy usually uses anthracycline or taxane based which can improve chemotherapy responses. Methods. This type of research is a CD8 + tumoral prognostic test used to predict neoadjuvant chemotherapy responses in patients with locally advanced breast cancer. The research was carried out in the oncology surgery clinic and inpatient Dr. Mohammad Hoesin Hospital Palembang. Assessment of CD8 + expression is done by immunohistochemistry. CD8 + expression is expressed as a percentage of cell expression, whose the cut off point is determined first. Result. There was a significant relationship between CD8 + tumoral with chemotherapy response (p = 0.033) with a sensitivity value: 43.5%; specificity: 100%, NR +: 100%; NR-: 35%; False positive: 0%; False negative: 65%; OR: 1.53. CD8 + predominantly had a good chemotherapy response in all samples of 10 (100%) patients while CD8 + non-dominant tumoral was more in a good chemotherapy response with 13 (65%) patients and poor chemotherapy response in 7 (35%) patient. Conclusion. CD8 + as a predictive factor for neoadjuvant chemotherapy responses in local advanced breast cancer has a significant relationship, with a p value = 0.033, sensitivity value: 43.5%; specificity: 100%, NR +: 100%; NR-: 35%; False positive: 0%; False negative: 65%.


Sign in / Sign up

Export Citation Format

Share Document